MODERN POSSIBILITIES FOR THE USE OF EMICIZUMAB IN HEMOPHILIA A: MECHANISM OF ACTION, CLINICAL EFFICACY AND SAFETY
Abstract
Hemophilia A is a hereditary coagulopathy associated with either quantitative deficiency or functional insufficiency of blood coagulation factor VIII, which leads to impaired formation of a stable fibrin clot and the development of hemorrhagic syndrome of varying severity. Although replacement therapy with factor VIII concentrates has long been the basis of pathogenetic treatment of this disease and has significantly improved patient survival, its clinical effectiveness remains limited in some cases due to the development of inhibitor forms, the need for repeated intravenous administration, variability of the hemostatic response, and insufficient control of spontaneous and recurrent bleeding episodes.
References
1. Oldenburg J., Mahlangu J.N., Kim B., et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors // New England Journal of Medicine. — 2017. — Vol. 377, No. 9. — P. 809–818. — DOI: 10.1056/NEJMoa1703068.
2. Mahlangu J., Oldenburg J., Paz-Priel I., et al. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors // New England Journal of Medicine. — 2018. — Vol. 379, No. 9. — P. 811–822. — DOI: 10.1056/NEJMoa1803550.
3. Young G., Liesner R., Chang T., et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors // Blood. — 2019. — Vol. 134, No. 24. — P. 2127–2138. — DOI: 10.1182/blood.2019001869.
4. Pipe S.W., Shima M., Lehle M., et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study // The Lancet Haematology. — 2019. — Vol. 6, No. 6. — P. e295–e305. — DOI: 10.1016/S2352-3026(19)30054-7.
5. Callaghan M.U., Negrier C., Paz-Priel I., et al. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1–4 studies // Blood. — 2021. — Vol. 137, No. 16. — P. 2231–2242. — DOI: 10.1182/blood.2020009217.
6. Yoneyama K., Schmitt C., Kotani N., et al. Approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A // Clinical Pharmacokinetics. — 2018. — Vol. 57, No. 9. — P. 1123–1134. — DOI: 10.1007/s40262-017-0616-3.
7. Retout S., Schmitt C., Petry C., et al. Population pharmacokinetic analysis and exposure–response assessment of emicizumab in people with hemophilia A // Clinical Pharmacokinetics. — 2020. — Vol. 59. — DOI: 10.1007/s40262-020-00904-z.
8. Mancuso M.E., Booth J., Buckner T.W., et al. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors: results from the HAVEN 2 study // Haemophilia. — 2020. — Vol. 26, No. 6. — P. 1009–1018. — DOI: 10.1111/hae.14183.
9. Srivastava A., Santagostino E., Dougall A., et al. WFH Guidelines for the Management of Hemophilia, 3rd edition // Haemophilia. — 2020. — Vol. 26, Suppl. 6. — P. 1–158.
10. Rodriguez-Merchan E.C., Valentino L.A. Emicizumab: review of the literature and critical appraisal // Haemophilia. — 2019. — Vol. 25, No. 1. — P. 11–20.
11. Andrade P.E.A., Mahlangu J.N., Pipe S.W., et al. Emicizumab: the hemophilia A game-changer // Haematologica. — 2024. — Vol. 109.
12. Chowdary P. Haemophilia // The Lancet. — 2025. — Review article on modern approaches to hemophilia management, including emicizumab.
